实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2014年
3期
330-332
,共3页
邓颖%胡洪林%杨兰%潘海霞%朱学强
鄧穎%鬍洪林%楊蘭%潘海霞%硃學彊
산영%호홍림%양란%반해하%주학강
培美曲塞%吉西他滨%顺铂%化疗
培美麯塞%吉西他濱%順鉑%化療
배미곡새%길서타빈%순박%화료
Pemetrexed%Gemcitabine%Cisplatin%Chemotherapy
目的:探讨培美曲塞与吉西他滨联合顺铂一线治疗晚期肺腺癌的近期疗效及不良反应。方法2009年2月至2012年12月收治的Ⅲb期及Ⅳ期肺腺癌60例,随机分为2组。实验组( PP组)30例,采用培美曲塞500 mg/m2静脉滴注,第1天;顺铂25 mg/m2静脉滴注,第1~3天,每3周为1个化疗周期。对照组( GP组)30例,采用吉西他滨1000 mg/m2静脉滴注,第1天;顺铂25 mg/m2静脉滴注,第1~3天,每3周为1个化疗周期。2个周期后进行疗效评价及不良反应评价。结果实验组和对照组有效率分别是30.0%和26.7%,疾病控制率分别为66.7%和70.0%,差异无统计学意义(P>0.05);不良反应显示实验组和对照组Ⅲ-Ⅳ度白细胞减少的发生率分别为13.3%(4/30)和40.0%(12/30),差异有统计学意义(P<0.05);Ⅲ-Ⅳ度贫血发生率分别为3.3%(1/30),6.7%(2/30),差异无统计学意义(P>0.05);Ⅲ-Ⅳ度血小板下降的发生率分别为6.7%(2/30),36.7%(11/30),差异有统计学意义(P<0.05)。肝肾功能损害差异无统计学意义;恶心呕吐发生率,2组差异无统计学意义;脱发的发生率实验组和对照组分别为10.0%(3/30),33.3%(10/30),差异有统计学意义(P<0.05)。结论培美曲塞联合顺铂治疗晚期肺腺癌疗效确切,且耐受性好。
目的:探討培美麯塞與吉西他濱聯閤順鉑一線治療晚期肺腺癌的近期療效及不良反應。方法2009年2月至2012年12月收治的Ⅲb期及Ⅳ期肺腺癌60例,隨機分為2組。實驗組( PP組)30例,採用培美麯塞500 mg/m2靜脈滴註,第1天;順鉑25 mg/m2靜脈滴註,第1~3天,每3週為1箇化療週期。對照組( GP組)30例,採用吉西他濱1000 mg/m2靜脈滴註,第1天;順鉑25 mg/m2靜脈滴註,第1~3天,每3週為1箇化療週期。2箇週期後進行療效評價及不良反應評價。結果實驗組和對照組有效率分彆是30.0%和26.7%,疾病控製率分彆為66.7%和70.0%,差異無統計學意義(P>0.05);不良反應顯示實驗組和對照組Ⅲ-Ⅳ度白細胞減少的髮生率分彆為13.3%(4/30)和40.0%(12/30),差異有統計學意義(P<0.05);Ⅲ-Ⅳ度貧血髮生率分彆為3.3%(1/30),6.7%(2/30),差異無統計學意義(P>0.05);Ⅲ-Ⅳ度血小闆下降的髮生率分彆為6.7%(2/30),36.7%(11/30),差異有統計學意義(P<0.05)。肝腎功能損害差異無統計學意義;噁心嘔吐髮生率,2組差異無統計學意義;脫髮的髮生率實驗組和對照組分彆為10.0%(3/30),33.3%(10/30),差異有統計學意義(P<0.05)。結論培美麯塞聯閤順鉑治療晚期肺腺癌療效確切,且耐受性好。
목적:탐토배미곡새여길서타빈연합순박일선치료만기폐선암적근기료효급불량반응。방법2009년2월지2012년12월수치적Ⅲb기급Ⅳ기폐선암60례,수궤분위2조。실험조( PP조)30례,채용배미곡새500 mg/m2정맥적주,제1천;순박25 mg/m2정맥적주,제1~3천,매3주위1개화료주기。대조조( GP조)30례,채용길서타빈1000 mg/m2정맥적주,제1천;순박25 mg/m2정맥적주,제1~3천,매3주위1개화료주기。2개주기후진행료효평개급불량반응평개。결과실험조화대조조유효솔분별시30.0%화26.7%,질병공제솔분별위66.7%화70.0%,차이무통계학의의(P>0.05);불량반응현시실험조화대조조Ⅲ-Ⅳ도백세포감소적발생솔분별위13.3%(4/30)화40.0%(12/30),차이유통계학의의(P<0.05);Ⅲ-Ⅳ도빈혈발생솔분별위3.3%(1/30),6.7%(2/30),차이무통계학의의(P>0.05);Ⅲ-Ⅳ도혈소판하강적발생솔분별위6.7%(2/30),36.7%(11/30),차이유통계학의의(P<0.05)。간신공능손해차이무통계학의의;악심구토발생솔,2조차이무통계학의의;탈발적발생솔실험조화대조조분별위10.0%(3/30),33.3%(10/30),차이유통계학의의(P<0.05)。결론배미곡새연합순박치료만기폐선암료효학절,차내수성호。
Objective To explore the efficacy and toxicities of pemetrexed or gemcitabine combined with cisplatin in the first-line treatment of advanced lung adenocarcinoma .Methods 60 cases of stage Ⅲb and stage Ⅳ lung adenocarcinoma were randomly divided into two groups.The experimental group (PP group) 30 cases,with pemetrexed 500 mg/m2 intravenous infusion of D1+cisplatin 25 mg/m2 intravenous infusion of D1-3,every 3 weeks for 1 cycle of chemotherapy .The control group ( GP group) 30 cases,with gemcitabine intravenous infusion of 1 000mg/m2 D1+and cisplatin 25 mg/m2 intravenous infusion of D1-3,every 3 weeks for 1 cycle of chemotherapy .Curative effects and adverse reactions were evaluated after 2 cycles.Results The efficiency of experimental group and control group were 30.0%and 26.7%,and disease control rates were 66.7%and 70.0%. There was no significant difference (P>0.05).Adverse reaction showed that grade Ⅲ-Ⅳleucopenia occurrence rates of the ex-perimental group and the control group were 13.3%(4/30) and 40.0%(12/30).The difference was statistically significant (P<0.05).GradeⅢ-Ⅳanemia incidence rates were 3.3%(1/30),and 6.7%(2/30),there was no significant difference (P>0.05);GradeⅢ-Ⅳthrombocytopenia occurrence rates were 6.7%(2/30),36.7%(11/30).The difference was statistical-ly significant(P<0.05).There was no statistical difference in liver and kidney function damage ,nausea and vomiting;the inci-dence of alopecia in experimental group and control group were 10.0%(3/30),and 33.3%(10/30),the difference was statisti-cal significant(P<0.05).Conclusion Pemetrexed combined with cisplatin is effective for advanced lung adenocarcinoma with tolerable side effects .